JP2022534302A5 - - Google Patents

Info

Publication number
JP2022534302A5
JP2022534302A5 JP2021570919A JP2021570919A JP2022534302A5 JP 2022534302 A5 JP2022534302 A5 JP 2022534302A5 JP 2021570919 A JP2021570919 A JP 2021570919A JP 2021570919 A JP2021570919 A JP 2021570919A JP 2022534302 A5 JP2022534302 A5 JP 2022534302A5
Authority
JP
Japan
Prior art keywords
ethynyl
pyrimidine
phenyl
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534302A (ja
JP7547387B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/065024 external-priority patent/WO2020239999A1/en
Publication of JP2022534302A publication Critical patent/JP2022534302A/ja
Publication of JP2022534302A5 publication Critical patent/JP2022534302A5/ja
Priority to JP2024146717A priority Critical patent/JP2024167319A/ja
Application granted granted Critical
Publication of JP7547387B2 publication Critical patent/JP7547387B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570919A 2019-05-31 2020-05-29 ＮＦ－κＢ誘導キナーゼの低分子阻害剤 Active JP7547387B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024146717A JP2024167319A (ja) 2019-05-31 2024-08-28 ＮＦ－κＢ誘導キナーゼの低分子阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US62/855,144 2019-05-31
US201962907833P 2019-09-30 2019-09-30
US62/907,833 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024146717A Division JP2024167319A (ja) 2019-05-31 2024-08-28 ＮＦ－κＢ誘導キナーゼの低分子阻害剤

Publications (3)

Publication Number Publication Date
JP2022534302A JP2022534302A (ja) 2022-07-28
JP2022534302A5 true JP2022534302A5 (enExample) 2023-06-05
JP7547387B2 JP7547387B2 (ja) 2024-09-09

Family

ID=71108552

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570919A Active JP7547387B2 (ja) 2019-05-31 2020-05-29 ＮＦ－κＢ誘導キナーゼの低分子阻害剤
JP2024146717A Pending JP2024167319A (ja) 2019-05-31 2024-08-28 ＮＦ－κＢ誘導キナーゼの低分子阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024146717A Pending JP2024167319A (ja) 2019-05-31 2024-08-28 ＮＦ－κＢ誘導キナーゼの低分子阻害剤

Country Status (37)

Country Link
US (2) US11254673B2 (enExample)
EP (2) EP4467199A3 (enExample)
JP (2) JP7547387B2 (enExample)
KR (1) KR20220027871A (enExample)
CN (2) CN118908957A (enExample)
AU (1) AU2020282005B2 (enExample)
BR (1) BR112021023796A2 (enExample)
CL (1) CL2021003142A1 (enExample)
CO (1) CO2021017838A2 (enExample)
CR (1) CR20210587A (enExample)
DK (1) DK3976597T3 (enExample)
DO (1) DOP2021000244A (enExample)
EC (1) ECSP21093623A (enExample)
ES (1) ES2989387T3 (enExample)
FI (1) FI3976597T3 (enExample)
HR (1) HRP20241352T1 (enExample)
HU (1) HUE068694T2 (enExample)
IL (1) IL288387B2 (enExample)
JO (1) JOP20210318B1 (enExample)
LT (1) LT3976597T (enExample)
MA (1) MA56038B1 (enExample)
MD (1) MD3976597T2 (enExample)
MX (1) MX2021014679A (enExample)
MY (1) MY205653A (enExample)
PE (1) PE20220768A1 (enExample)
PH (1) PH12021553011A1 (enExample)
PL (1) PL3976597T3 (enExample)
PT (1) PT3976597T (enExample)
RS (1) RS66105B1 (enExample)
SA (1) SA521430960B1 (enExample)
SG (1) SG11202112994WA (enExample)
SI (1) SI3976597T1 (enExample)
SM (1) SMT202400418T1 (enExample)
TW (2) TWI850390B (enExample)
UA (1) UA130430C2 (enExample)
UY (1) UY38721A (enExample)
WO (1) WO2020239999A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
US20250304567A1 (en) * 2022-05-11 2025-10-02 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
WO2026029041A1 (ja) * 2024-07-30 2026-02-05 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
EP1773781A2 (en) * 2004-08-03 2007-04-18 Wyeth Indazoles useful in treating cardiovascular diseases
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
JP2011525915A (ja) 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
MX2013010513A (es) * 2011-03-16 2013-10-07 Hoffmann La Roche Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
US9034866B2 (en) 2012-02-17 2015-05-19 Genentech, Inc. Tricyclic compounds and methods of use therefor
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CN105658639A (zh) * 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
JP2016533385A (ja) 2013-08-22 2016-10-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
EP3209654B1 (en) 2014-10-23 2018-10-03 Janssen Pharmaceutica N.V. New pyrazole derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
EA033238B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные тиенопиримидина в качестве ингибиторов nik
KR102523405B1 (ko) 2014-10-23 2023-04-18 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
CN109863142B (zh) * 2016-08-24 2022-06-10 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
KR102662373B1 (ko) 2017-07-06 2024-04-29 얀센 파마슈티카 엔브이 Nik 억제제로서의 신규 치환 아자인돌린 유도체
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores

Similar Documents

Publication Publication Date Title
JP2022534302A5 (enExample)
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
IL310992A (en) NLRP3 inhibitors
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
JP2020531498A5 (enExample)
JP2022500402A5 (enExample)
JP2024532733A (ja) 複素環式化合物及び使用方法
CN118974055A (zh) 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
US9108970B2 (en) Fused heteroaromatic pyrrolidinones
TWI766281B (zh) 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
CN118715215A (zh) 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
JP2020050682A (ja) ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤
RU2424242C2 (ru) Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
US20130310340A1 (en) Method of treating muscular degradation
JP2016537384A5 (enExample)
JP2013508404A5 (enExample)
JP2014527959A5 (enExample)
RU2011116447A (ru) Модуляторы амилоида бета
JP2020526549A5 (enExample)
JP2018522859A5 (enExample)
HRP20170285T1 (hr) Heterociklilamini kao inhibitori pi3k
JP2017518326A5 (enExample)
JP2018529731A5 (enExample)
JP2012527483A (ja) ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
RU2016140338A (ru) Азаспиро производные в качестве антагонистов trpm8